Back
Top 0.5%
19.1%
#1
19.1%
Top 64%
8.4%
Top 0.7%
6.4%
Top 0.4%
6.0%
Top 0.7%
4.2%
Top 10%
4.2%
Top 0.4%
4.2%
Top 34%
2.3%
Top 78%
2.1%
Top 5%
2.0%
Top 2%
1.6%
Top 56%
1.4%
Top 18%
1.3%
Top 6%
0.8%
Top 1%
0.8%
Top 7%
0.8%
Top 12%
0.8%
Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors
2024-05-02
oncology
Title + abstract only
View on medRxiv
Show abstract
ObjectiveDual checkpoint inhibitor therapy with nivolumab and ipilimumab has been FDA-approved for a number of cancer sites. However, their role in the treatment of ACC and other salivary gland carcinomas is not well established. Methods and analysisWe performed a Simons two-stage prospective single-institution phase II clinical trial of nivolumab with ipilimumab. Two cohorts were analyzed: patients with metastatic/recurrent ACC and patients with other salivary gland cancers. The primary endpoi...
Predicted journal destinations
1
Cancers
57 training papers
2
Frontiers in Oncology
34 training papers
3
PLOS ONE
1737 training papers
4
Clinical Cancer Research
22 training papers
5
British Journal of Cancer
22 training papers
6
Cancer Medicine
17 training papers
7
eLife
262 training papers
8
BMC Cancer
21 training papers
9
Nature Communications
483 training papers
10
Scientific Reports
701 training papers
11
Frontiers in Immunology
140 training papers
12
Diagnostics
36 training papers
13
BMJ Open
553 training papers
14
JAMA Network Open
125 training papers
15
International Journal of Molecular Sciences
39 training papers
16
International Journal of Cancer
18 training papers
17
PeerJ
46 training papers
18
iScience
74 training papers